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CASE REPORT
Myasthenia gravis is an autoimmune disease that
affects the neuromuscular junction and has occa-
sionally been found in conjunction with other
autoimmune diseases, such as rheumatoid arthri-
tis, systemic lupus erythematosus, and thyroidi-
tis.1 There have also been a few reports of the
association of myasthenia gravis with pernicious
anemia.2,3 Multiple autoantibodies, such as anti-
parietal cell and anti-intrinsic factor antibodies,
have also been demonstrated in some myasthe-
nia gravis patients.3,4 It is speculated that these
associations represent a constellation of hyper-
immunity syndromes. Here, we report an elderly
Taiwanese woman who developed myasthenia
gravis in the course of pernicious anemia.
Case Report
A 73-year-old woman was admitted to our hospital
with an 8-month history of oral and lingual pain
in September 2002. She was neither a vegetarian
nor an alcoholic. She had no history of hyper-
cthyroidism, diabetes mellitus, alopecia, or celia
disease. Physical examination showed beefy red
tongue with atrophic papillae and mild cheilosis.
yThe liver and spleen were impalpable. Laborator
fstudies showed a red blood cell (RBC) count o
1.4 × 1012/L (normal range, 4.5–5.9 × 1012/L), he-
moglobin of 66 g/L (normal range, 45–59 g/L),
hematocrit of 19.1% (normal range, 41–53%),
mean corpuscular volume (MCV) of 134 fL (nor-
rmal range, 80–100 fL), and mean corpuscula
hemoglobin of 46 pg (normal range, 26–34 pg).
White blood cell count was 3.8 × 109/L (normal
range, 3.8–10.6×109/L) with 54% segmented neu-
trophils, 40.5% lymphocytes, 2% monocytes, 2%
eosinophils, 1% atypical lymphocytes, and 0.5%
basophils. Platelet count was 122 × 109/L (normal
range, 150–400 × 109/L). Serum levels of electro-
lytes, glucose, blood urea nitrogen, creatine, aspar-
tate aminotransferase, alanine aminotransferase,
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γ-glutamyl transpeptidase, and total bilirubin were
all within normal limits. Thyroid screening tests,
including free T4 and thyroid-stimulating hor-
mone, were unremarkable.
Diagnostic studies for anemia showed a de-
creased level of serum vitamin B12 (<36.9 pmol/L;
normal range, 118.1–715.9 pmol/L) and a positive
gastric parietal cell antibody (titer, 1:80). Serum
folate level was normal. Microscopic examination
of a peripheral blood smear showed marked hy-
persegmented neutrophils. Bone marrow aspirate
showed megaloblastic hematopoiesis. Atrophic
gastric mucosa with absence of parietal cells and
chronic inflammation were observed on esopha-
geal endoscopic biopsy. Based on the clinical
and laboratory findings, pernicious anemia was
diagnosed.
After 3 months of hydroxocobalamine treat-
ment, the oral and lingual pain subsided. Five
months later, RBC count, hemoglobin, hematocrit,
and MCV were 4.42 × 1012/L, 126 g/L, 39.8%,
and 90.0 fL, respectively. She was re-admitted in
February 2003, however, due to bilateral ptosis.
During the second course of hospitalization,
binocular diplopia was noted, with free range of
eye movement. The pupils were normal in size and
promptly reactive to light. Muscle strength was
normal in the face and four limbs. Edrophonium
hydrochloride administered intravenously in a
dose of 10 mg produced a dramatic improvement
in ptosis. Nerve conduction studies of the four
limbs were normal. Repetitive nerve stimulation
at 3 Hz demonstrated a 60% decremental response
of the compound muscle action potential amp-
litude in the deltoid muscle and a 36% decre-
mental response in the triceps muscle. Serum
anti-acetylcholine receptor antibody was 5.36
nmol/L (normal, <0.2 nmol/L). Myasthenia gravis
was diagnosed based on the clinical and labora-
tory findings. Thoracic computed tomography
revealed no evidence of thymoma.
Ptosis and diplopia improved markedly 
after pyridostigmine (60 mg, 4 times per day)
and oral prednisolone therapy (20 mg daily).
Regular pyridostigmine and hydroxocobalamine
administration was continued. Prednisolone was
tapered and stopped 7 months after discharge,
and repetitive nerve fstimulation at the rate o
3 Hz demonstrated no significant decremental
response. She experienced no recurrence of anemia
or myasthenic symptoms over a 2-year follow-up
at our outpatient clinics.
Discussion
yPernicious anemia is a chronic illness caused b
impaired absorption of vitamin B12. It is an auto-
timmune disease due to atrophic gastritis tha
produces autoantibodies to the gastric parietal
cells or intrinsic factors.5 The clinical manifesta-
tions of pernicious anemia include beefy tongue,
loss of papillae, lingual and oral burning pain.6
The pathologic features of aspirated bone mar-
row were hypercellularity with large erythroid
precursors and hypersegmented neutrophils.7
Subacute combined degeneration of the lateral
yand dorsal column of the spinal cord is usuall
noted as the neurologic presentation.8 The pres-
ent case had characteristic features of pernicious
anemia including macrocystic anemia, mega-
loblastic hematopoiesis, positive gastric anti-
fparietal cell antibody and a low serum level o
vitamin B12. The development of ptosis and
diplopia later raised the possibility of myasthe-
nia gravis. The symptoms of both diseases were
markedly improved after medical treatment.
Myasthenia gravis is an autoimmune disease
associated with the presence of anti-acetylcholine
receptor antibody.9 This autoantibody binds to
rthe postsynaptic nicotinic acetylcholine recepto
and blocks neuromuscular transmission.9 rOthe
autoimmune diseases, such as systemic lupus
erythematosus, polymyositis, rheumatoid arthritis,
and Hashimoto’s thyroiditis are present in 5–10%
of patients with myasthenia gravis.1 However, the
combination of myasthenia gravis and hemato-
logic autoimmune fdiseases is rare. A few cases o
pernicious anemia, hemolytic anemia, pure red
cell aplasia, thrombotic thrombocytopenic purpura
and acute lymphoblastic leukemia associated
with myasthenia gravis have been reported.1,3,10
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Simpson reported a total of nine cases of perni-
cious anemia in 491 patients with myasthenia
gravis—an incidence of 1.83%, and concluded
that the incidence of pernicious anemia in pa-
tients with myasthenia gravis is higher than in
the normal population.11 However, a review of the
data from our previous study of 390 patients
with myasthenia gravis in this hospital, diag-
nosed based on clinical features and confirmed
by positive anti-acetylcholine receptor antibody
and/or decremental repetitive nerve stimulation
response, revealed that only one patient (0.26%)
had pernicious anemia.12 From among the 390
patients in that study, 33 (8.46%) had thy-
roiditis, two (0.51%) had systemic lupus erythe-
matosus, two (0.51%) had rheumatoid arthritis,
one (0.26%) had Sjögren’s syndrome, and one
(0.26%) had multiple sclerosis. In addition to
one case of pernicious anemia, two other cases
of myasthenia gravis concomitant with anemia
(one case with thalassemia and the other with
aplastic anemia) were found in the series. The re-
sult of the study indicated that the incidence of
pernicious anemia in Taiwanese patients with
myasthenia gravis (0.26%) is lower than that 
reported in Caucasian patients (1.83%).11 The
discrepancy may be attributable to genetic differ-
ences, different sampling methods, the possibil-
ity that occurrence of both disorders may simply
be coincidental, or to different immunopatho-
geneses involved in myasthenia gravis associ-
ated with pernicious anemia in Taiwanese and
Caucasians.
Pernicious anemia and myasthenia gravis
may share a common cause of autoimmunity. It
is possible that different antibodies to various
tissues can be expressed in the same patient.
Downes et al found gastric parietal cell antibod-
ies in 12% of 74 myasthenic patients.13 Zittoun
et al reported a total of three (3.7%) patients
with anti-intrinsic factor antibodies in a study 
of 81 patients with myasthenia gravis.4 Other 
autoantibodies, such as antithyroid and antinu-
clear antibodies, were also found in some patients
with myasthenia gravis.14 On the other hand,
ysuch autoantibodies were also found occasionall
in patients with pernicious anemia.15 Therefore,
gthese two diseases may be classified as involvin
systemic autoimmunity. Determination of the ex-
trinsic or intrinsic factors that trigger the produc-
tion of these organ-specific autoantibodies will
require further study.
A multicenter study of patients with myasthe-
nia gravis in Italy reported that 70% had hyper-
plasia of the thymus and 10% had thymoma.16
gA study from the USA reported that amon  
patients with coexisting pernicious anemia and
myasthenia gravis, 9% developed thymoma.2
tThymectomy may result in a striking improvemen
rin patients with systemic lupus erythematosus o
autoimmune hemolytic anemia occurring coin-
cidentally with myasthenia gravis.17,18 However,
the benefit of thymectomy in patients with coex-
isting myasthenia gravis and pernicious anemia
has not been established. In this patient, myas-
ythenia gravis and pernicious anemia were easil
controlled with pyridostigmine and prednisolone,
rand hydroxocobalamine, respectively. As regula
hydroxocobalamine administration was contin-
rued during follow-up in this case, it is not clea
whether the pernicious anemia was cured by pred-
nisolone treatment. However, a good response to
rshort-term steroid treatment may suggest a lowe
ylevel of autoimmunity and that thymectomy ma
not be necessary.
Although existing data suggest that the co-
existence of myasthenia gravis and pernicious
anemia is rare in the Taiwanese population, the
presence of pernicious anemia must still be ruled
out in any patient with myasthenia gravis who
feature anemia or posterior-column symptoms.
Conversely, ptosis, diplopia or muscle weakness
in a patient with pernicious anemia should arouse
gsuspicion of myasthenia gravis. Antibody testin
rin a patient with myasthenia gravis to screen fo
the full range of concomitant autoimmune dis-
eases may be indicated. Recognition of the combi-
nation of myasthenia gravis and pernicious anemia
is important because the therapeutic result is
rewarding.
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